Search

The article discusses the intra-host evolution of Parvovirus B19 during relapsing infections in immunocompromised patients. Through whole genome sequencing, researchers observed mutations in the viral genome and subsequent protein changes over time. One patient developed mutations in the VP1/2 region, which led to conformational changes in the capsid protein near the antibody binding domain. The study highlights the importance of understanding viral evolution and immune responses in treating B19V infections in immunocompromised individuals. [Extracted from the article]

A recent study conducted at the University of Wisconsin Madison focused on the impact of colostrogenesis on the circulating serum titer against canine parvovirus (CPV-2) in pregnant dogs. The researchers aimed to determine the optimal timing for serum sample collection to achieve the best diagnostic accuracy and to investigate the hypothesis that active transport and sequestration of immunoglobulin type G (IgG) specific for CPV-2 leads to a temporary decline in circulating anti-CPV-2 antibody titer. The study found that serum samples collected during the colostrogenesis window showed a significant decrease in circulating anti-parvovirus titer, suggesting that samples should be collected outside of this window for the greatest accuracy. [Extracted from the article]

A recent study conducted by researchers at National University Colombia aimed to classify and understand the genetic differences of porcine parvoviruses (PPVs). The study analyzed PPV1 to PPV7 genome sequences from Colombia and other sequences available in the GenBank database. The researchers found that PPV3 had the highest prevalence among the tested gilts, followed by PPV5, PPV6, PPV1, PPV2, PPV4, and PPV7. The study also revealed two main clades within PPV1 and significant genetic distances between PPV2 to PPV7 and other PPV genomes worldwide. This research contributes to the phylogenetic classification and evolutionary studies of PPVs and highlights their endemic circulation in Colombian pig herds. [Extracted from the article]

A study conducted in Babylon Province, Iraq, investigated the prevalence, susceptibility rate, and risk factors of human parvovirus B19 (B19-V) in women aged 15 to 45. Blood samples were taken from 116 women, and tests revealed that 44% of the participants had B19-V IgG antibodies, indicating past infection, while 16.5% had B19-V IgM antibodies, indicating recent infection. Factors associated with higher seroprevalence rates included age, history of abortion, education, unemployment, and overcrowding. The study suggests that pregnant women, especially those with a history of bad obstetric history, should undergo regular screening for B19-V to improve pregnancy outcomes. [Extracted from the article]

A study conducted by researchers at Wasit University has been published, focusing on the serological detection of Human Parvovirus B19 in thalassemia patients in the Wasit Province. The study found that Human Parvovirus B19, a nonenvelope single-strand DNA virus from the Parvoviridae family, is strongly related to thalassemia. The study included 120 thalassemia patients, with 10.8% testing positive for Human Parvovirus B19. The research also noted that males had a higher prevalence of the virus compared to females. [Extracted from the article]

A recent report discusses research on sickle cell anemia and its connection to parvovirus B19 infections. The study focused on children with sickle cell disease (SCD) who experienced transient red cell aplasia (TRCA) due to the virus. The researchers found that some patients had unusually high white blood cell count and absolute neutrophil count values. They also identified two distinct immune cell profiles, one associated with successful adaptive immunity and virus control, and the other associated with cell activation. The study suggests the need for a parvovirus B19 vaccine to prevent complications in SCD patients. [Extracted from the article]

Researchers at Poznan University of Medical Sciences in Poland have conducted a study on parvovirus B19 infection in pregnancy. Parvovirus B19 is a virus that typically causes a harmless infection in children and adults. However, if the virus is transmitted during pregnancy, it can have serious consequences for both the pregnant woman and the fetus. Complications can include severe fetal anemia, fetal edema, and mirror syndrome in pregnant women. The study presents eight cases of parvovirus B19 infection in pregnant women, highlighting the various complications and discussing diagnostic and treatment strategies. [Extracted from the article]

A recent study from Uttar Pradesh, India, reports on a rare case of coinfection with Parvovirus B19 and Plasmodium vivax in a young boy with malaria. The researchers found that Parvovirus B19 can cause bone-marrow suppression, reticulocytopenia, and anemia in malaria patients. The patient was treated with chloroquine for malaria, but the anemia persisted, leading to a bone-marrow aspiration that revealed erythroid suppression and the presence of Parvovirus B19-specific antibodies. The patient received supportive treatment and blood transfusions, and after three months, he was asymptomatic with normal blood counts. This case highlights the importance of considering Parvovirus B19 infection in cases of chronic anemia, even when other causes are known. [Extracted from the article]

A new study from Nanchong Vocational and Technical College in China explores the features and distribution of CpG islands in the genomes of porcine parvovirus (PPV). PPV is a reproductive disorder in sows that can lead to miscarriage, stillbirth, and mummification. The study found that different subtypes of PPV have varying numbers of CpG islands, which are known to impact the life cycle of viruses. This research provides a foundation for potential antiviral treatment strategies for PPV from an epigenetic perspective. [Extracted from the article]

A recent study conducted in China by MSD Animal Health has found that feline parvovirus (FPV) continues to be a significant health concern for cats, despite routine vaccination practices. The study analyzed 152 rectal swabs from diseased cats and detected FPV DNA in 17 of the samples. Genetic analysis revealed that the predominant group of FPV in infected cats in China is FPV-G1. The researchers recommend further investigation into the genotypic and evolutionary characteristics of FPV to improve prevention strategies. [Extracted from the article]

A report from Wuhan Keqian Biology Co. Ltd. in Wuhan, People's Republic of China, discusses the development of a recombinant Lactobacillus plantarum oral vaccine for preventing feline panleukopenia virus (FPV). Traditional vaccines for FPV can induce stress and adverse reactions, so there is a need for a safer and more gentle vaccination method. The study found that the recombinant L. plantarum NC8/VP2 effectively colonizes the feline intestinal tract and induces high levels of neutralizing antibodies through oral administration. This research presents a promising approach for disease prevention in domestic cats. [Extracted from the article]

Researchers from Anhui Agricultural University in China have developed a new method for detecting feline panleukopenia virus (FPV), a highly prevalent and consequential disease in cats. The method, called recombinase polymerase amplification-lateral flow dipstick assay (RPA-LFDA), demonstrated superior sensitivity and specificity compared to existing techniques. It was capable of detecting as low as 10 target copies per reaction and showed no interference from other viruses. The researchers concluded that the RPA-LFDA method offers greater convenience and cost-effectiveness for the clinical detection of FPV compared to other methods. [Extracted from the article]

A recent study conducted by researchers at the Capital Institute of Pediatrics in Beijing, China, has provided new insights into the genetic makeup of human bocavirus (HBoV). The study found that head-to-tail sequences were present in HBoV genotype 1 among children with acute respiratory infections. These sequences were highly diverse in length and sequences, suggesting a switch of template chains during the replication process. The findings contribute to a better understanding of HBoV and its potential impact on respiratory infections in children. [Extracted from the article]

A study conducted at the IRCCS Humanitas Research Hospital in Italy has found that acute Parvovirus B19 infection can be misclassified as a systemic rheumatic disease. Parvovirus B19 is known to cause erythema infectiosum, or fifth disease, in children, but it can also affect adults and lead to rheumatologic symptoms that mimic autoimmune conditions. The study evaluated 54 patients with acute Parvovirus B19 infection and found that nearly all patients with positive serum antinuclear antibodies (ANA) fulfilled the classification criteria for systemic lupus erythematosus (SLE). The researchers emphasize the importance of considering the risk of misclassification in patients with viral infections. [Extracted from the article]

A study conducted by the Chinese Academy of Agricultural Sciences in Harbin, People's Republic of China, has developed a quadruplex real-time quantitative PCR method for the detection of four important pathogens in ducks: Muscovy duck parvovirus (MDPV), Goose parvovirus (GPV), Duck circovirus (DuCV), and Duck adenovirus 3 (DAdV-3). The assay showed no cross-reactivity with other poultry pathogens and had a high sensitivity and accuracy. The study concluded that this method provides a rapid, sensitive, specific, and accurate technique for clinical testing of these viruses in ducks. [Extracted from the article]

A study conducted at Muljibhai Patel Urological Hospital in Gujarat, India, has found that kidney transplant recipients are at a higher risk for parvovirus B19 (PVB19) infection, which can lead to refractory anemia and increased morbidity. The study reviewed the charts of patients who underwent kidney transplantation between May 2013 and March 2022 and found that 1.9% of patients had PVB19 disease, with symptoms including fatigue, fever, dyspnea, and myalgia. All patients developed anemia, and graft dysfunction was observed in 61.9% of patients. The primary treatment for PVB19 infection involves reducing immunosuppressants, especially antiproliferative agents. [Extracted from the article]

A recent report from the University of Milan in Italy discusses the clinical presentations of Parvovirus B19 (PVB19) in pediatric cases. PVB19 is a DNA virus that commonly causes asymptomatic infections or mild flu-like symptoms. The report presents three cases of PVB19 infection in children, each with distinct manifestations including rashes, vasculitis, and thrombocytopenia. The research emphasizes the importance of diagnosing PVB19, particularly during peak seasons, and highlights the potential complications of the infection, such as thrombocytopenia. Understanding the epidemiological patterns of PVB19 can aid in managing outbreaks and minimizing its impact on pediatric health. [Extracted from the article]

The article highlights research conducted by University Hospital Tuebingen on the implications of Parvovirus B19 in childhood myocarditis, emphasizing its impact on young patients. Topics discussed include the frequency of B19V infection in acute versus chronic myocarditis, the correlation between viral loads and immune response in children, and the importance of comprehensive histopathological and molecular analyses for timely diagnosis and treatment.

A recent study conducted by the University of Florence in Italy explores the role of Parvovirus B19 (B19V) in rheumatic diseases. B19V is a human pathogen that infects and replicates in erythroid progenitor cells in the bone marrow, leading to their apoptosis. The virus can also infect other cell types and modify their normal physiology. The study suggests that B19V may be involved in the pathogenesis of autoimmune rheumatologic diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, systemic sclerosis, systemic lupus erythematosus, and vasculitis. The research provides basic information on the virus, highlights characteristics of viral infection, and focuses on recent findings regarding its role in rheumatologic diseases. [Extracted from the article]

A study conducted by researchers at the Chinese Academy of Agricultural Sciences explores the production of virus-like particle (VLP) vaccines using a cost-effective Escherichia coli expression system. The study focuses on the assembly of porcine parvovirus VLPs and investigates the effect of structural changes in the lipid A of Escherichia coli on endotoxin activity, immunogenicity, and safety. The results show that the VLPs produced from the modified Escherichia coli strain have high immunogenicity and minimal endotoxin activity, making them a promising option for vaccine production. This research offers a method to address the issue of endotoxin residues in VLPs and provides production benefits. [Extracted from the article]

A patent application has been submitted for a therapeutic composition that aims to treat liver fibrosis, a condition that impairs liver function. The invention proposes the use of a viral vector derived from Parvovirus or adeno-associated virus (AAV) to deliver nucleic acid sequences encoding specific transcription factors. These transcription factors aim to induce the differentiation of fibroblasts into hepatocytes, inhibit collagen deposition, and restore liver function. The patent application provides detailed information on the composition, methods of administration, and potential therapeutic applications of the invention. [Extracted from the article]

This document is a patent application for a method of treating schizophrenia and bipolar disorder. The method involves identifying a specific sequence of a novel open reading frame (nORF) associated with these disorders and administering an inhibitor to reduce the expression of the nORF. The inhibitor can be a small molecule, polynucleotide, or polypeptide, and it can be delivered using a viral vector. Alternatively, the method also includes providing a protein encoded by the nORF to the subject to treat the disorders. The patent application provides detailed claims and descriptions of the methods. [Extracted from the article]

A study conducted by researchers at Cleveland Clinic Florida examined the prevalence of Parvovirus B19 (B19V) and Parvovirus 4 (PARV4) infections among healthy blood donors in Iran. The study involved 400 blood donors who were tested for B19V and PARV4 nucleic acids, as well as anti-B19V IgM and IgG antibodies. The results showed that 3% of individuals tested positive for B19V DNA, 1.5% tested positive for PARV4 DNA, 2% displayed positive results for anti-B19V IgM, and 76.5% exhibited positive results for anti-B19V IgG. The researchers concluded that systematic screening and exclusion should be implemented for individuals at high risk to minimize potential contamination risks. [Extracted from the article]

A recent study conducted in Suzhou, China investigated the prevalence of human parvovirus B19 infection among voluntary blood donors. The study found that out of 893 blood donor samples collected, the overall seroprevalence of B19 antibodies was 20.7%, with 19.4% testing positive for anti-B19 IgG and 1.9% testing positive for anti-B19 IgM. The prevalence of anti-B19 IgG increased with age, and repeated blood donors had a higher rate of anti-B19 IgG compared to first-time donors. Three cases were also found to be positive for B19 DNA. The study concluded that while the prevalence of B19 infection in Suzhou was lower than in other areas, there was still a risk of transmission through blood transfusions, particularly for high-risk and susceptible groups. [Extracted from the article]

A recent study conducted at Tianjin Children's Hospital in China compared the clinical characteristics of children with plastic bronchitis caused by human bocavirus type 1 (HBoV1) and Mycoplasma pneumoniae (MP) infections. The study found that children with HBoV1-PB had milder symptoms but higher white blood cell counts compared to those with MP-PB. The MP-PB group exhibited elevated levels of fibrinogen and d-dimer, as well as increased inflammatory indicators. The study highlights the differences in inflammation and coagulation responses between HBoV1 and MP infections, providing valuable insights for clinical diagnosis and treatment. [Extracted from the article]

A recent study conducted by the Medical University of Silesia in Poland has provided new data on heart failure, specifically focusing on viral myocarditis as a factor leading to the development of heart failure symptoms. The study found that parvovirus B19 (PVB19) has become the main virus associated with myocarditis, replacing previously dominant viruses. The research also highlighted a correlation between PVB19 infection and the risk of developing inflammatory dilated cardiomyopathy (DCMi). However, the study acknowledges that more research is needed to determine whether PVB19 is a causative factor or simply accompanies these conditions. [Extracted from the article]

A study conducted at the Suzhou Blood Center in China investigated the presence of parvovirus B19 (B19V) infection among blood donors. The study found that the prevalence of B19V antibodies and DNA was lower in the Suzhou region compared to the rest of China, suggesting a relatively low risk of B19V transmission through transfusion. However, the study emphasized the importance of paying attention to susceptible populations, particularly those in high-risk groups, during transfusion. The research provides valuable insights into the status of B19V infection in Eastern China. [Extracted from the article]

The article focuses on a study investigating the oncolytic effects of the rat protoparvovirus H-1 (H-1PV) against cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin lymphoma. The research demonstrates that H-1PV induces oncolysis in CTCL models without affecting healthy donor cells and enhances immune cell infiltration in spheroid co-cultures. The study concludes that H-1PV shows promise as a viroimmunotherapeutic agent for treating CTCL.

A recent study conducted by researchers at the University of Bern challenges the current understanding of how human parvovirus B19 (B19V) enters cells. The study suggests that B19V enters cells through a mechanism mediated by the glycosphingolipid globoside, without disrupting the endosomal membrane. The researchers found that globoside is an essential intracellular receptor required for the virus to escape the endosome. This study provides new insights into the entry process of B19V and highlights the importance of globoside in facilitating viral infection. [Extracted from the article]

Researchers from the University of Florida have made progress in studying the Parvovirus B19, a human pathogen that causes diseases in infants and adults. The researchers focused on the VP1u component of the virus, which is essential for infection. They were able to determine the structure of the receptor-binding domain (RBD) of the VP1u using NMR resonance assignments. This information can be used for further studies and the development of antivirals specific to the RBD domain. The research was supported by the National Science Foundation and the State of Florida. [Extracted from the article]

A preprint abstract from biorxiv.org challenges the current understanding of how human parvovirus B19 (B19V) enters cells. It suggests that B19V enters erythroid progenitor cells through a mechanism mediated by the glycosphingolipid globoside, without disrupting the endosome or undergoing retrograde transport to the Golgi. The study found that B19V phospholipase A2 (PLA2) activity requires specific calcium levels and pH conditions that are not optimal in endosomes, and that globoside knockout cells are unable to facilitate endosomal escape of the virus. The research suggests that globoside is an essential intracellular receptor for B19V entry. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted by researchers from Ahvaz Jundishapur University of Medical Sciences in Iran explored the prevalence and clinical significance of Human Parvovirus 4 (P4) in individuals with sickle cell disease (SCD). The study found that the prevalence of P4 and its co-prevalence with primate erythroparvovirus 1 (B19) was significantly higher in SCD patients compared to healthy individuals. However, the prevalence of P4 did not show a significant correlation with age, sex, aplastic crises, or specific complications associated with SCD. This research suggests that SCD patients are more susceptible to P4 infection. [Extracted from the article]

A recent report from the University of Kansas Medical Center discusses the findings of a study on parvovirus. The study focused on Human bocavirus 1 (HBoV1), a parvovirus that causes respiratory tract infections in young children. The researchers discovered that a small noncoding RNA called bocavirus-encoded small RNA (BocaSR) undergoes N6-methyladenosine (m6A) modification, which is crucial for viral DNA replication. The modified BocaSR acts as a mediator for recruiting Y-family DNA repair DNA polymerases, facilitating viral DNA replication. This study provides insight into the involvement of a viral small noncoding RNA in viral DNA replication through m6A modification. [Extracted from the article]

A recent study conducted by researchers from Al-Azhar University in Cairo, Egypt, focused on the human Bocavirus 1 (HBoV1) and its association with acute lower respiratory tract infections in Egyptian infants. The study enrolled 100 infants aged 4 weeks to 2 years who presented with symptoms of acute respiratory infection. The researchers found that HBoV1 infection was present in 8% of the studied patients, with the highest infection rates occurring in January, April, and July. The study concluded that HBoV1 infection may be considered a risk factor for lower respiratory tract infections in Egyptian children under 2 years old. [Extracted from the article]

A patent has been issued for a small noncoding RNA called BocaSR, which is found in the genome of Human bocavirus 1 (HBoV1). BocaSR is essential for the replication of HBoV1 DNA and plays a direct role in viral DNA replication. It has potential applications in antiviral therapies and the production of recombinant HBoV vectors. The patent also describes a vector system that can be used to prevent, inhibit, or treat bocaparvovirus infection in mammals, as well as a method for producing recombinant adeno-associated virus (rAAV) using a helper virus-free method. [Extracted from the article]